Arix’s £181m market capitalisation is 15 per cent less than the combined value of its £139m (108p) cash pile and the £73m (56.5p) listed portfolio. You are getting a free ride on the group’s £53m (41p) unlisted portfolio.
Simon Thompson put it into his 2021 bargain portfolio, but it has been the worst performer YTD.
I am holding it, but so far its dropped about 30%, however, I've read Simons comments and also done my own research and long-term I still think its a winner.
I've held it past my usual cut-off point, but I want some biotech/healthcare exposure and recognise that this area can be highly volatile, so I will hang on and hope that one or two of its holdings become the catalyst for a re-rate. There are a couple of holdings which look like they really could take off.
